New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
10:41 EDTRH, JD, FIO, NSR, OPEN, LULU, NWBO, ULTA, MONT, OREXOptions with decreasing implied volatility
Options with decreasing implied volatility: OREX MONT ULTA NWBO LULU OPEN NSR FIO JD RH
News For OREX;MONT;ULTA;NWBO;LULU;OPEN;NSR;FIO;JD;RH From The Last 14 Days
Check below for free stories on OREX;MONT;ULTA;NWBO;LULU;OPEN;NSR;FIO;JD;RH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 10, 2014
15:04 EDTLULULululemon Athletica September 38.5 weekly straddle priced for 7.7% move into Q2
Subscribe for More Information
13:51 EDTLULUlululemon technical commentary ahead of results
Subscribe for More Information
13:25 EDTLULUEarnings Preview: Lululemon could report 'sharply' lower Q2 profit
Subscribe for More Information
07:22 EDTRHRestoration Hardware September volatility elevated into Q2 and outlook
Subscribe for More Information
September 9, 2014
15:27 EDTOREXOrexigen volatility elevated
Subscribe for More Information
12:46 EDTOREXNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
09:50 EDTLULULululemon Athletica September volatility increases into Q2
Subscribe for More Information
08:37 EDTRHRestoration Hardware set-up favorable into earnings, says Jefferies
Jefferies views the set-up for shares of Restoration Hardware as favorable into the company's Q2 results Wednesday night. The firm believes Restoration can top the high-end of sales guidance and that concerns around product margin are overblown. Jefferies notes that as of mid-August, the short interest in the name was 21% of the float at 7.4M shares. It believes shorting the stock into the earnings announcement would be "unwise" and keeps a Buy rating on Restoration Hardware with an $88 price target.
06:39 EDTLULUlululemon valuation unattractive ahead of results, says Deutsche Bank
Deutsche Bank says lululemon's valuation is unattractive ahead of the company's Q2 results on Thursday morning. Deutsche sees a lack of visibility on when comps will improve and remains cautious on the stock with a Hold rating and $35 price target.
September 8, 2014
17:22 EDTOREXOrexigen, Takeda Pharmaceutical in services agreement
Orexigen disclosed in a regulatory filing that in preparation for the potential launch of NB32, Orexigen Therapeutics (OREX) and Takeda Pharmaceutical Company (TKPYY) entered into a Manufacturing Services Agreement, dated September 2, in accordance with the Collaboration Agreement between the company and Takeda, effective as of September 1, 2010, as amended by Amendment Number 1 to Collaboration Agreement effective as of September 26, 2013. Pursuant to the Agreement, among other things, the company will supply to Takeda, and Takeda will, subject to certain exceptions as set forth in the Agreement and Collaboration Agreement, exclusively purchase from the Company, all of Takeda’s requirements of NB32 for commercialization in the United States, Canada and Mexico during the term of the Collaboration Agreement. The Agreement will continue in full force and effect until the expiration or termination of the Collaboration Agreement.
06:42 EDTLULUlululemon expected to report sharply lower profit, WSJ reports
lululemon is expected to report a sharply lower profit, with analysts expecting a profit of $42.7M in the latest quarter, reports the Wall Street Journal. Investors will be watching for signs the self-inflicted problems are getting resolved after executives said overhauling the company's process will take about 18 months. Reference Link
September 5, 2014
15:21 EDTLULULululemon Athletica September volatility elevated into Q2
Subscribe for More Information
11:47 EDTMONTOptions with increasing implied volatility
Subscribe for More Information
07:49 EDTLULUlululemon challenges persisted in Q2, says Canaccord
Canaccord said the product assortment at lululemon remains stale and the firm sees traffic, product flow, fashion quotient and conversion challenges persisting in Q2. The firm believes the brand remains relevant and has long-term growth opportunities but there are likely to be more fits and starts in the interim. Canaccord keeps its Hold rating and $42 price target on shares of lululemon.
06:34 EDTLULUlululemon estimates lowered ahead of Q2 report at Barclays
Subscribe for More Information
September 4, 2014
13:05 EDTLULULululemon Athletica September volatility elevated into Q2
Lululemon Athletica September 12 weekly call option implied volatility is at 72, September is at 56, October is at 46, January is at 37; compared to its 26-week average of 38 according to Track Data, suggesting larger September price movement into the expected release of Q2 on September 11.
10:34 EDTULTAUlta Salon September volatility increases into Q2 and outlook
Subscribe for More Information
09:03 EDTNSRNeuStar, comScore announce partnership to improve brands' digital ad delivery
Subscribe for More Information
September 2, 2014
08:18 EDTOREXOrexigen receives new US patent related to NB32 intellectual property
Orexigen announced that the U.S. Patent and Trademark Office has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone and bupropion. The patent expires in 2024. If NB32 is approved for use in the United States, Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration. A counterpart application to this patent has issued in Europe and other international jurisdictions.
07:22 EDTULTAUlta Salon remains a quality growth idea, says RW Baird
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use